Send to:

Choose Destination
See comment in PubMed Commons below
Pharmacogenomics. 2014 May;15(7):909-14. doi: 10.2217/pgs.14.47.

Warfarin dose requirements in a patient with the CYP2C9*14 allele.

Author information

  • 1Department of Pharmacy Practice, University of Illinois at Chicago, Chicago, IL 60612-7230, USA.


We describe a 64-year-old male of Indian descent with a history of atrial fibrillation who was started on warfarin after hospital admission for acute stroke. He received genotype-guided warfarin dosing as per the standard-of-care at our hospital, with daily dose recommendations provided by the pharmacogenetics service. Genotyping revealed the rare CYP2C9*1/*14 genotype and warfarin insensitive VKORC1 -1639GG and CYP4F2 433Met/Met genotypes. The patient received an initial warfarin loading dose of 4 mg for 2 days, followed by 2-3 mg/day for the following 11 days. He reached a therapeutic international normalized ratio on day 5, which was maintained over the following week. This report adds to the limited data of the effects of the CYP2C9*14 allele on warfarin dose requirements.


CYP2C9*14; VKORC1; anticoagulation; pharmacogenetics; warfarin

[PubMed - indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Atypon Icon for PubMed Central
    Loading ...
    Write to the Help Desk